This site is intended for US healthcare professionals.

Tolerability

Tolerability

~80% of patients were able to stay on FOTIVDA without stopping due to side effects, and 76% were able to take full dose without reducing due to side effects1,2

Bar chart comparing interruptions, reductions, and discontinuations between FOTIVDA and sorafenib with percentage values.

Learn about dosing.

See More

See results from the pivotal trial.

View PFS

Reach out to an AVEO Oncology Account Manager.

Get in Touch

For guidance on dose modifications for adverse reactions, see package insert.

References: 1. FOTIVDA (tivozanib) [package insert]. Boston, MA: AVEO Pharmaceuticals, Inc, August 2024. 2. Data on file, AVEO Pharmaceuticals, Inc., 2021.